Tyr424

Site Information
RLIEDNEytARQGAK SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 448234
Associated spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	2D analysis ( 74 ) , [32P] bio-synthetic labeling ( 130 , 131 ) , flow cytometry ( 27 ) , immunoprecipitation ( 6 , 9 , 10 , 19 , 40 , 41 , 43 , 49 ) , mass spectrometry ( 10 , 11 , 14 , 16 , 18 , 20 , 21 , 22 , 30 , 33 , 37 , 38 , 39 , 42 , 47 , 48 , 50 , 52 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 62 , 64 , 67 , 69 , 71 , 72 , 75 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 96 , 97 , 98 , 100 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 116 , 117 , 119 , 120 , 121 , 122 , 123 , 124 ) , microscopy-colocalization with upstream kinase ( 9 ) , mutation of modification site ( 4 , 6 , 10 , 45 , 68 , 118 , 131 ) , phospho-antibody ( 1 , 2 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 12 , 13 , 15 , 19 , 23 , 24 , 25 , 26 , 28 , 31 , 32 , 34 , 35 , 36 , 40 , 41 , 43 , 44 , 45 , 46 , 49 , 51 , 53 , 61 , 65 , 66 , 68 , 70 , 73 , 74 , 76 , 95 , 99 , 101 , 115 , 125 , 126 , 127 , 128 , 129 ) , phosphopeptide mapping ( 130 , 131 ) , western blotting ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 12 , 13 , 15 , 19 , 23 , 24 , 25 , 26 , 28 , 31 , 32 , 34 , 35 , 36 , 40 , 41 , 43 , 44 , 45 , 46 , 49 , 51 , 53 , 61 , 65 , 66 , 68 , 70 , 73 , 74 , 76 , 115 , 125 , 126 )
Disease tissue studied:	breast cancer ( 1 ) , lung cancer ( 4 , 62 ) , non-small cell lung cancer ( 37 , 62 ) , lymphoma ( 113 ) , neuroblastoma ( 13 ) , pancreatic cancer ( 23 ) , pancreatic carcinoma ( 23 ) , pituitary cancer ( 46 ) , melanoma skin cancer ( 24 ) , cancer, squamous cell carcinoma ( 26 )
Relevant cell line - cell type - tissue:	'3T3-L1, differentiated' (adipocyte) ( 11 ) , 'brain, cerebral cortex' ( 47 , 127 ) , 'brain, striatum' ( 45 ) , 'fat, brown' ( 33 ) , 'muscle, smooth'-thoracic aorta ( 68 ) , 'neuron, cortical'-brain ( 43 , 126 , 128 ) , 'renal, podocyte' ( 7 , 19 ) , 'stem, embryonic' ( 48 ) , 293 (epithelial) ( 4 , 65 , 68 , 126 , 129 ) , 293F (epithelial) ( 8 , 51 ) , 32D (myeloid) [IRS1 (mouse)] ( 101 ) , 3T3 (fibroblast) [Pyk2 (human), transfection, stable Pyk2 (v5-His tagged) transfection, in RU-486 (mifepristone)-inducible expression system] ( 42 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 131 ) , 3T3 (fibroblast) [Src (human)] ( 112 ) , 3T3 (fibroblast) ( 28 , 41 , 49 , 105 , 106 , 107 , 108 , 119 , 120 , 121 , 122 , 123 , 124 , 130 ) , 3T3-L1 (fibroblast) ( 66 , 75 ) , 831/13 ( 116 , 117 ) , AB.1 (T lymphocyte) ( 34 ) , AtT20 (pituitary cell) ( 46 ) , B lymphocyte ( 2 ) , B16 (melanocyte) ( 24 ) , BaF3 ('B lymphocyte, precursor') ( 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 96 , 97 , 98 , 100 , 114 ) , bone marrow ( 5 ) , brain ( 21 , 33 , 39 ) , C2C12 (myoblast) ( 54 , 55 , 56 , 57 , 58 , 59 ) , C3H10T1/2 (fibroblast) ( 70 ) , C4HD (breast cell) ( 95 ) , CL1-5 (pulmonary) ( 4 ) , colon ( 10 ) , COS (fibroblast) ( 73 ) , embryo ( 36 ) , FG (pancreatic) ( 23 ) , FL5.12 (lymphoid) ( 101 ) , GD25 (fibroblast) ( 125 ) , heart ( 18 ) , HEK293-A (epithelial) ( 10 ) , HeLa (cervical) ( 6 ) , hematopoietic stem cells ( 27 ) , HL-1 (myocyte) [Akt1 (mouse), knockdown, stable lentiviral expression of Akt1 shRNA] ( 16 ) , HL-1 (myocyte) [Akt2 (mouse), knockdown, stable lentiviral expression of Akt2 shRNA] ( 16 ) , HL-1 (myocyte) ( 16 ) , HUVEC (endothelial) ( 31 ) , keratinocyte-skin ( 51 ) , kidney ( 33 ) , liver ( 20 , 67 ) , liver [leptin (mouse), homozygous knockout] ( 20 ) , lung ( 33 , 37 , 69 ) , macrophage ( 73 ) , MC3T3-E1 (preosteoblast) ( 40 ) , MCP-5 (mast) ( 64 ) , MDA-MB-231 (breast cell) ( 1 ) , MEF (fibroblast) [p53 (mouse), homozygous knockout] ( 30 ) , MEF (fibroblast) [PTP1B (mouse), homozygous knockout] ( 52 ) , MEF (fibroblast) [PTPN2 (mouse), homozygous knockout] ( 53 ) , MEF (fibroblast) [Src iso1 (mouse)] ( 60 ) , MEF (fibroblast) ( 6 , 36 , 52 , 60 , 61 , 65 , 71 , 73 , 76 ) , megakaryocyte ( 35 ) , myocyte-heart ( 61 ) , Neuro-2a (neuron) ( 13 ) , neuron-'brain, hippocampus' ( 13 ) , neutrophil ( 44 ) , osteoblast ( 40 ) , osteoclast ( 118 ) , osteoclast-like cell ( 129 ) , PC-12 (chromaffin) ( 99 ) , prostate ( 25 ) , RAW 264.7 (macrophage) ( 9 , 14 ) , RAW 267.4 (macrophage) ( 50 ) , Sor4 ( 103 , 109 ) , Sor577 ( 102 , 111 ) , SorA ( 104 , 110 ) , spermatozoa ( 74 ) , spinal cord ( 32 ) , spleen ( 33 ) , splenocyte-spleen ( 8 ) , squamous [FAK iso2 (mouse), homozygous knockout] ( 26 ) , Swiss 3T3 (fibroblast) ( 115 ) , SYF (fibroblast) [Src iso1 (mouse), transfection] ( 22 ) , SYF (fibroblast) ( 3 , 61 ) , T lymphocyte-lymph node ( 38 ) , vessel ( 15 ) , VSMC ( 15 )

Upstream Regulation
Regulatory protein:	ACF7 (mouse) ( 51 ) , AR (mouse) ( 25 ) , CD44 (mouse) ( 73 ) , CD74 (mouse) ( 73 ) , CMIP (mouse) ( 19 ) , CSK (mouse) ( 19 ) , DNAJB4 (human) ( 4 ) , ERG (mouse) ( 25 ) , FAK iso2 (mouse) ( 26 , 36 ) , GAB2 (mouse) ( 5 ) , GPM6A (human) ( 13 ) , GRK5 (mouse) ( 68 ) , IFITM3 (human) ( 2 ) , IFITM3 (rat) ( 2 ) , Israa (mouse) ( 8 ) , Klra17 (mouse) ( 44 ) , KOR-1 (mouse) ( 46 ) , KRas (mouse) ( 25 ) , PPP2CA (human) ( 35 ) , PTPN2 (human) ( 53 ) , PTPN2 (mouse) ( 53 ) , PTPRA (human) ( 63 ) , PTPRA (mouse) ( 76 ) , RHOC (mouse) ( 24 ) , Src iso1 (mouse) ( 22 , 24 , 60 )
Kinases, in vitro:	Src (human) ( 65 ) , Src iso1 (mouse) ( 130 )
Putative upstream phosphatases:	PTPN2 (mouse) ( 9 ) , PTPRO (human) ( 3 )
Phosphatases, in vitro:	PTPN2 (mouse) ( 9 )
Treatments:	1-butanol ( 99 ) , 1Na-PP1 ( 43 ) , angiotensin_2 ( 15 , 19 ) , antibody ( 8 , 38 , 129 ) , aphidicolin ( 53 ) , BDNF ( 43 ) , caffeine ( 53 ) , calmidazolium ( 126 ) , cAMP_analog ( 74 ) , cell_adhesion ( 51 ) , chloroquine ( 26 ) , colforsin ( 32 ) , CPCCOEt ( 126 ) , dasatinib ( 26 , 40 ) , dexamethasone ( 70 ) , DHPG ( 126 ) , EGF ( 1 , 23 , 49 , 70 , 99 ) , epoxomicin ( 26 ) , estradiol ( 127 ) , fibronectin ( 63 ) , fMLP ( 44 ) , forced swim test ( 45 ) , Freund's_complete_adjuvant ( 32 ) , GF109203X ( 66 , 126 ) , H-89 ( 32 , 74 ) , H2O2 ( 34 , 61 , 76 , 99 ) , high-fat diet ( 28 ) , IBMX ( 70 ) , IGF-1 ( 1 , 23 ) , imatinib ( 101 ) , ionomycin ( 34 ) , LPS ( 9 ) , MIF ( 73 ) , mifepristone ( 95 ) , MK801 ( 126 ) , MMS ( 53 ) , MPA ( 95 , 101 ) , MPEP ( 126 ) , MSP ( 23 ) , nocodazole ( 41 ) , ophiobolin ( 126 ) , osmotic_stress ( 115 ) , palmitate ( 28 ) , palmitoleic_acid ( 28 ) , PDGF ( 1 , 61 , 66 , 68 ) , phorbol_ester ( 61 , 126 ) , PIP3 ( 2 ) , PKCI_19-27 ( 126 ) , polyunsaturated_fatty_acid ( 28 ) , PP1 ( 43 , 61 ) , PP2 ( 70 , 73 , 95 , 99 , 127 ) , PTX ( 74 ) , saturated_fatty_acid ( 28 ) , serum ( 1 ) , serum_starvation ( 65 ) , SU6656 ( 15 , 53 ) , t-butanol ( 99 ) , TCDD ( 70 ) , thapsigargin ( 34 ) , thymidine ( 53 ) , U50488 ( 46 ) , UV ( 53 ) , vanadate ( 131 ) , W-7 ( 126 ) , Zn(2+) ( 43 )

Downstream Regulation
Effects of modification on Src iso1:	activity, induced ( 131 ) , enzymatic activity, induced ( 3 , 118 ) , molecular association, regulation ( 127 ) , phosphorylation ( 1 )
Effects of modification on biological processes:	cell differentiation, altered ( 40 ) , cytoskeletal reorganization ( 118 )
Induce interaction with:	GRB2 (mouse) ( 127 )

Disease / Diagnostics Relevance
Relevant diseases:	HER2 positive breast cancer ( 1 )

References
1	Song L, et al. (2020) Proto-oncogene Src links lipogenesis via lipin-1 to breast cancer malignancy. Nat Commun 11, 5842 33203880 Curated Info
2	Lee J, et al. (2020) IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells. Nature 588 33149299 Curated Info
3	Roth L, et al. (2019) Phosphorylation of the phosphatase PTPROt at Tyr is a molecular switch that controls osteoclast activity and bone mass in vivo. Sci Signal 12 30622194 Curated Info
4	Chen CH, et al. (2016) HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms. Oncogene 35, 5674-5685 27065329 Curated Info
5	Gu S, et al. (2016) Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. Blood 127, 1803-13 26773044 Curated Info
6	Liu X, et al. (2016) Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies. Proc Natl Acad Sci U S A 113, 984-9 26755576 Curated Info
7	Verma R, et al. (2016) Integrin Ligation Results in Nephrin Tyrosine Phosphorylation In Vitro. PLoS One 11, e0148906 26848974 Curated Info
8	Ben Khalaf N, Taha S, Bakhiet M, Fathallah MD (2016) A Central Nervous System-Dependent Intron-Embedded Gene Encodes a Novel Murine Fyn Binding Protein. PLoS One 11, e0149612 26901312 Curated Info
9	Ha Thi HT, et al. (2016) Protein Tyrosine Phosphatase N2 Is a Positive Regulator of Lipopolysaccharide Signaling in Raw264.7 Cell through Derepression of Src Tyrosine Kinase. PLoS One 11, e0162724 27611995 Curated Info
10	Murata Y, et al. (2015) Protein tyrosine phosphatase SAP-1 protects against colitis through regulation of CEACAM20 in the intestinal epithelium. Proc Natl Acad Sci U S A 112, E4264-71 26195794 Curated Info
11	Parker BL, et al. (2015) Targeted phosphoproteomics of insulin signaling using data-independent acquisition mass spectrometry. Sci Signal 8, rs6 26060331 Curated Info
12	Beristain AG, et al. (2015) PKA signaling drives mammary tumorigenesis through Src. Oncogene 34, 1160-73 24662820 Curated Info
13	Formoso K, Billi SC, Frasch AC, Scorticati C (2015) Tyrosine 251 at the C-terminus of neuronal glycoprotein M6a is critical for neurite outgrowth. J Neurosci Res 93, 215-29 25242528 Curated Info
14	Pinto SM, et al. (2015) Quantitative phosphoproteomic analysis of IL-33-mediated signaling. Proteomics 15, 532-44 25367039 Curated Info
15	Qin B, Zhou J (2015) Src Family Kinases (SFK) Mediate Angiotensin II-Induced Myosin Light Chain Phosphorylation and Hypertension. PLoS One 10, e0127891 26011449 Curated Info
16	Reinartz M, Raupach A, Kaisers W, Gödecke A (2014) AKT1 and AKT2 induce distinct phosphorylation patterns in HL-1 cardiac myocytes. J Proteome Res 13, 4232-45 25162660 Curated Info
17	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
18	Lundby A, et al. (2013) In vivo phosphoproteomics analysis reveals the cardiac targets of β-adrenergic receptor signaling. Sci Signal 6, rs11 23737553 Curated Info
19	Yu L, et al. (2013) Inhibition of nephrin activation by c-mip through Csk-Cbp-Fyn axis plays a critical role in Angiotensin II-induced podocyte damage. Cell Signal 25, 581-8 23200848 Curated Info
20	Grimsrud PA, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metab 16, 672-83 23140645 Curated Info
21	Trinidad JC, et al. (2012) Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. Mol Cell Proteomics 11, 215-29 22645316 Curated Info
22	Ferrando IM, et al. (2012) Identification of targets of c-Src tyrosine kinase by chemical complementation and phosphoproteomics. Mol Cell Proteomics 11, 355-69 22499769 Curated Info
23	Huang M, et al. (2012) EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation. Oncogene 31, 2783-93 21963850 Curated Info
24	Arpaia E, et al. (2012) The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk. Oncogene 31, 884-96 21765460 Curated Info
25	Drake JM, et al. (2012) Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A 109, 1643-8 22307624 Curated Info
26	Sandilands E, et al. (2012) Autophagic targeting of Src promotes cancer cell survival following reduced FAK signalling. Nat Cell Biol 14, 51-60 22138575 Curated Info
27	Miharada K, et al. (2011) Cripto regulates hematopoietic stem cells as a hypoxic-niche-related factor through cell surface receptor GRP78. Cell Stem Cell 9, 330-44 21982233 Curated Info
28	Holzer RG, et al. (2011) Saturated fatty acids induce c-Src clustering within membrane subdomains, leading to JNK activation. Cell 147, 173-84 21962514 Curated Info
29	Oneyama C, et al. (2011) MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene 30, 3489-501 21383697 Curated Info
30	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
31	Xu K, et al. (2011) Blood vessel tubulogenesis requires Rasip1 regulation of GTPase signaling. Dev Cell 20, 526-39 21396893 Curated Info
32	Yang HB, et al. (2011) cAMP-dependent protein kinase activated Fyn in spinal dorsal horn to regulate NMDA receptor function during inflammatory pain. J Neurochem 116, 93-104 21054385 Curated Info
33	Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89 21183079 Curated Info
34	Lysechko TL, Cheung SM, Ostergaard HL (2010) Regulation of the tyrosine kinase Pyk2 by calcium is through production of reactive oxygen species in cytotoxic T lymphocytes. J Biol Chem 285, 31174-84 20688918 Curated Info
35	Pradhan S, et al. (2010) Cross-talk between serine/threonine protein phosphatase 2A and protein tyrosine phosphatase 1B regulates Src activation and adhesion of integrin αIIbβ3 to fibrinogen. J Biol Chem 285, 29059-68 20615878 Curated Info
36	Lim ST, et al. (2010) Knock-in mutation reveals an essential role for focal adhesion kinase activity in blood vessel morphogenesis and cell motility-polarity but not cell proliferation. J Biol Chem 285, 21526-36 20442405 Curated Info
37	Carretero J, et al. (2010) Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 17, 547-59 20541700 Curated Info
38	Iwai LK, Benoist C, Mathis D, White FM (2010) Quantitative phosphoproteomic analysis of T cell receptor signaling in diabetes prone and resistant mice. J Proteome Res 9, 3135-45 20438120 Curated Info
39	Wiśniewski JR, et al. (2010) Brain phosphoproteome obtained by a FASP-based method reveals plasma membrane protein topology. J Proteome Res 9, 3280-9 20415495 Curated Info
40	Lee YC, et al. (2010) Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 29, 3196-207 20228840 Curated Info
41	Vacaru AM, den Hertog J (2010) Serine Dephosphorylation of Receptor Protein Tyrosine Phosphatase {alpha} in Mitosis Induces Src Binding and Activation. Mol Cell Biol 30, 2850-61 20385765 Curated Info
42	Bonnette PC, et al. (2010) Phosphoproteomic characterization of PYK2 signaling pathways involved in osteogenesis. J Proteomics 73, 1306-20 20116462 Curated Info
43	Huang YZ, McNamara JO (2010) Mutual regulation of Src family kinases and the neurotrophin receptor TrkB. J Biol Chem 285, 8207-17 20064930 Curated Info
44	Sasawatari S, et al. (2010) The Ly49Q receptor plays a crucial role in neutrophil polarization and migration by regulating raft trafficking. Immunity 32, 200-13 20153219 Curated Info
45	Taniguchi S, et al. (2009) Involvement of NMDAR2A tyrosine phosphorylation in depression-related behaviour. EMBO J 28, 3717-29 19834457 Curated Info
46	Clayton CC, Xu M, Chavkin C (2009) Tyrosine phosphorylation of Kir3 following kappa-opioid receptor activation of p38 MAPK causes heterologous desensitization. J Biol Chem 284, 31872-81 19773548 Curated Info
47	Tweedie-Cullen RY, Reck JM, Mansuy IM (2009) Comprehensive mapping of post-translational modifications on synaptic, nuclear, and histone proteins in the adult mouse brain. J Proteome Res 8, 4966-82 19737024 Curated Info
48	Li H, et al. (2009) SysPTM: a systematic resource for proteomic research on post-translational modifications. Mol Cell Proteomics 8, 1839-49 19366988 Curated Info
49	Chung BM, et al. (2009) The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants. Oncogene 28, 1821-32 19305428 Curated Info
50	Trost M, et al. (2009) The phagosomal proteome in interferon-gamma-activated macrophages. Immunity 30, 143-54 19144319 Curated Info
51	Wu X, Kodama A, Fuchs E (2008) ACF7 regulates cytoskeletal-focal adhesion dynamics and migration and has ATPase activity. Cell 135, 137-48 18854161 Curated Info
52	Mertins P, et al. (2008) Investigation of protein-tyrosine phosphatase 1B function by quantitative proteomics. Mol Cell Proteomics 7, 1763-77 18515860 Curated Info
53	Shields BJ, et al. (2008) DNA replication stalling attenuates tyrosine kinase signaling to suppress S phase progression. Cancer Cell 14, 166-79 18691551 Curated Info
54	Possemato A (2008) CST Curation Set: 4931; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
55	Possemato A (2008) CST Curation Set: 4932; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
56	Possemato A (2008) CST Curation Set: 4933; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
57	Possemato A (2008) CST Curation Set: 4934; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
58	Possemato A (2008) CST Curation Set: 4935; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
59	Possemato A (2008) CST Curation Set: 4929; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
60	Luo W, et al. (2008) Global impact of oncogenic Src on a phosphotyrosine proteome. J Proteome Res 7, 3447-60 18563927 Curated Info
61	Rybin VO, et al. (2008) Phorbol 12-myristate 13-acetate-dependent protein kinase C delta-Tyr311 phosphorylation in cardiomyocyte caveolae. J Biol Chem 283, 17777-88 18387943 Curated Info
62	Rikova K (2008) CST Curation Set: 4252; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
63	Wu L, et al. (2008) Distinct FAK-Src activation events promote alpha5beta1 and alpha4beta1 integrin-stimulated neuroblastoma cell motility. Oncogene 27, 1439-48 17828307 Curated Info
64	Cao L, et al. (2007) Quantitative time-resolved phosphoproteomic analysis of mast cell signaling. J Immunol 179, 5864-76 17947660 Curated Info
65	Radziwill G, et al. (2007) Regulation of c-Src by binding to the PDZ domain of AF-6. EMBO J 26, 2633-44 17491594 Curated Info
66	Artemenko Y, Gagnon A, Ibrahim S, Sorisky A (2007) Regulation of PDGF-stimulated SHIP2 tyrosine phosphorylation and association with Shc in 3T3-L1 preadipocytes. J Cell Physiol 211, 598-607 17219406 Curated Info
67	Villén J, Beausoleil SA, Gerber SA, Gygi SP (2007) Large-scale phosphorylation analysis of mouse liver. Proc Natl Acad Sci U S A 104, 1488-93 17242355 Curated Info
68	Wu JH, et al. (2006) Regulation of the platelet-derived growth factor receptor-beta by G protein-coupled receptor kinase-5 in vascular smooth muscle cells involves the phosphatase Shp2. J Biol Chem 281, 37758-72 17018529 Curated Info
69	Farnsworth C (2006) CST Curation Set: 2094; Year: 2006; Biosample/Treatment: tissue, lung/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
70	Liu X, Jefcoate C (2006) 2,3,7,8-tetrachlorodibenzo-p-dioxin and epidermal growth factor cooperatively suppress peroxisome proliferator-activated receptor-gamma1 stimulation and restore focal adhesion complexes during adipogenesis: selective contributions of Src, Rho, and Erk distinguish these overlapping processes in C3H10T1/2 cells. Mol Pharmacol 70, 1902-15 16971554 Curated Info
71	Li Y (2006) CST Curation Set: 2049; Year: 2006; Biosample/Treatment: cell line, MEF/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
72	Zhou J (2006) CST Curation Set: 1969; Year: 2006; Biosample1/Treatment/Isotope: tissue, brain/untreated/L, Biosample2/Treatment/Isotope: tissue, brain/untreated/H; Disease: -; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: YXp[ST] Curated Info
73	Shi X, et al. (2006) CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25, 595-606 17045821 Curated Info
74	Baker MA, Hetherington L, Aitken RJ (2006) Identification of SRC as a key PKA-stimulated tyrosine kinase involved in the capacitation-associated hyperactivation of murine spermatozoa. J Cell Sci 119, 3182-92 16835269 Curated Info
75	Schmelzle K, et al. (2006) Temporal dynamics of tyrosine phosphorylation in insulin signaling. Diabetes 55, 2171-9 16873679 Curated Info
76	Hao Q, Rutherford SA, Low B, Tang H (2006) Selective regulation of hydrogen peroxide signaling by receptor tyrosine phosphatase-alpha. Free Radic Biol Med 41, 302-10 16814111 Curated Info
77	Goss V (2006) CST Curation Set: 1403; Year: 2006; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
78	Goss V (2006) CST Curation Set: 1404; Year: 2006; Biosample/Treatment: cell line, BaF3/serum starved &'\|\|' IL3 starvation &'\|\|' Tpo; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
79	Goss V (2006) CST Curation Set: 1405; Year: 2006; Biosample1/Treatment/Isotope: cell line, BaF3/none/L, Biosample2/Treatment/Isotope: cell line, BaF3/none/H; Disease: chronic myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
80	Goss V (2006) CST Curation Set: 1406; Year: 2006; Biosample1/Treatment/Isotope: cell line, BaF3/serum starved &'\|\|' IL3 starvation &'\|\|' Tpo/L, Biosample2/Treatment/Isotope: cell line, BaF3/serum starved &'\|\|' IL3 starvation &'\|\|' Tpo/H; Disease: chronic myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
81	Gu T (2006) CST Curation Set: 1311; Year: 2006; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
82	Goss V (2006) CST Curation Set: 1200; Year: 2006; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
83	Gu T (2005) CST Curation Set: 1058; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
84	Goss V (2005) CST Curation Set: 861; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
85	Goss V (2005) CST Curation Set: 862; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
86	Goss V (2005) CST Curation Set: 847; Year: 2005; Biosample/Treatment: cell line, BaF3/serum starved; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
87	Goss V (2005) CST Curation Set: 848; Year: 2005; Biosample/Treatment: cell line, BaF3/serum starved; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
88	Gu T (2005) CST Curation Set: 844; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
89	Gu T (2005) CST Curation Set: 845; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
90	Gu T (2005) CST Curation Set: 846; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
91	Goss V (2005) CST Curation Set: 814; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
92	Goss V (2005) CST Curation Set: 813; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
93	Goss V (2005) CST Curation Set: 815; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
94	Goss V (2005) CST Curation Set: 816; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
95	Proietti C, et al. (2005) Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol Cell Biol 25, 4826-40 15923602 Curated Info
96	Goss V (2005) CST Curation Set: 698; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
97	Gu T (2005) CST Curation Set: 699; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
98	Gu T (2005) CST Curation Set: 700; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
99	Banno Y, et al. (2005) Implication of phospholipase D2 in oxidant-induced phosphoinositide 3-kinase signaling via Pyk2 activation in PC12 cells. J Biol Chem 280, 16319-24 15705590 Curated Info
100	Goss V (2005) CST Curation Set: 670; Year: 2005; Biosample/Treatment: cell line, BaF3/serum starved &'\|\|' Tpo; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
101	Gu JJ, Santiago L, Mitchell BS (2005) Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl. Blood 105, 3270-7 15604220 Curated Info
102	Boccalatte F (2005) CST Curation Set: 635; Year: 2005; Biosample/Treatment: cell line, Sor577/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
103	Boccalatte F (2005) CST Curation Set: 636; Year: 2005; Biosample/Treatment: cell line, Sor4/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
104	Boccalatte F (2005) CST Curation Set: 637; Year: 2005; Biosample/Treatment: cell line, SorA/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
105	Guo A (2005) CST Curation Set: 629; Year: 2005; Biosample/Treatment: cell line, 3T3/serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
106	Guo A (2005) CST Curation Set: 630; Year: 2005; Biosample/Treatment: cell line, 3T3/EGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
107	Guo A (2005) CST Curation Set: 631; Year: 2005; Biosample/Treatment: cell line, 3T3/serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
108	Guo A (2005) CST Curation Set: 633; Year: 2005; Biosample/Treatment: cell line, 3T3/serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
109	Boccalatte F (2005) CST Curation Set: 566; Year: 2005; Biosample/Treatment: cell line, Sor4/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
110	Boccalatte F (2005) CST Curation Set: 567; Year: 2005; Biosample/Treatment: cell line, SorA/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
111	Boccalatte F (2005) CST Curation Set: 568; Year: 2005; Biosample/Treatment: cell line, Sor577/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
112	Rush J, et al. (2005) Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23, 94-101 15592455 Curated Info
113	Boccalatte F (2004) CST Curation Set: 500; Year: 2004; Biosample/Treatment: cell line, Tg 543/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
114	Goss V (2004) CST Curation Set: 496; Year: 2004; Biosample/Treatment: cell line, BaF3/serum starved; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
115	Lunn JA, Rozengurt E (2004) Hyperosmotic stress induces rapid focal adhesion kinase phosphorylation at tyrosines 397 and 577. Role of Src family kinases and Rho family GTPases. J Biol Chem 279, 45266-78 15302877 Curated Info
116	Li Y (2004) CST Curation Set: 381; Year: 2004; Biosample/Treatment: cell line, 831/13/Serum starved &'\|\|' IGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
117	Li Y (2004) CST Curation Set: 382; Year: 2004; Biosample/Treatment: cell line, 831/13/Serum starved &'\|\|' Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
118	Miyazaki T, et al. (2004) Src kinase activity is essential for osteoclast function. J Biol Chem 279, 17660-6 14739300 Curated Info
119	Moritz A (2004) CST Curation Set: 265; Year: 2004; Biosample/Treatment: cell line, 3T3/serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
120	Moritz A (2003) CST Curation Set: 206; Year: 2003; Biosample/Treatment: cell line, 3T3/NRG1; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
121	Moritz A (2003) CST Curation Set: 209; Year: 2003; Biosample/Treatment: cell line, 3T3/NRG1; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
122	Moritz A (2003) CST Curation Set: 150; Year: 2003; Biosample/Treatment: cell line, 3T3/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
123	Moritz A (2003) CST Curation Set: 151; Year: 2003; Biosample/Treatment: cell line, 3T3/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
124	Moritz A (2003) CST Curation Set: 90; Year: 2003; Biosample/Treatment: cell line, 3T3/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
125	Pankov R, et al. (2003) Specific beta1 integrin site selectively regulates Akt/protein kinase B signaling via local activation of protein phosphatase 2A. J Biol Chem 278, 18671-81 12637511 Curated Info
126	Heidinger V, et al. (2002) Metabotropic glutamate receptor 1-induced upregulation of NMDA receptor current: mediation through the Pyk2/Src-family kinase pathway in cortical neurons. J Neurosci 22, 5452-61 12097497 Curated Info
127	Nethrapalli IS, et al. (2001) Estradiol (E2) elicits SRC phosphorylation in the mouse neocortex: the initial event in E2 activation of the MAPK cascade? Endocrinology 142, 5145-8 11713208 Curated Info
128	Manzerra P, et al. (2001) Zinc induces a Src family kinase-mediated up-regulation of NMDA receptor activity and excitotoxicity. Proc Natl Acad Sci U S A 98, 11055-61 11572968 Curated Info
129	Sanjay A, et al. (2001) Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility. J Cell Biol 152, 181-95 11149930 Curated Info
130	Pu M, et al. (1996) Evidence of a novel redox-linked activation mechanism for the Src kinase which is independent of tyrosine 527-mediated regulation. Oncogene 13, 2615-22 9000135 Curated Info
131	Kmiecik TE, Johnson PJ, Shalloway D (1988) Regulation by the autophosphorylation site in overexpressed pp60c-src. Mol Cell Biol 8, 4541-6 2460746 Curated Info